HLAtyping Panel v2.0 参考最新数据库 (Version 3.50)，靶向 11 个 HLA 基因 (I 类：HLA-A、B、C；II 类：HLA-DPA1、DPB1、DQA1、DAQB1、DRB1/3/4/5)，探针覆盖全部等位基因的全长基因组序列，可支持到第四数段的高精度分型。

结合目前数据库快速增长以及全长序列不断丰富的背景，我们推出了 HLAtyping Panel v2.0，参考最新数据库 (3.50 版)，靶向 11 个 HLA 基因 (I 类：HLA-A、B、C; II类：HLA-DPA1、DPB1、DQA1、DQB1、DRB1/3/4/5)，探针覆盖全部等位基因的全长基因组序列，可支持到第四数段的高 …

2021年10月5日 · Compared with a widely used HLA reference panel with European-only individuals (the Type 1 Diabetes Genetics Consortium 11 (T1DGC)), this new reference panel has a sixfold increase in the...

2 天之前 · What is the panel-reactive antibody percentage, and how does it relate to HLA testing? The panel-reactive antibody (PRA) percentage is an estimate of the percentage of the donor population that a specific organ recipient might be incompatible with due to preformed human leukocyte antigen (HLA) antibodies.

The TruSight HLA v2 Sequencing Panel (originally developed by Illumina and now available from CareDx) enables phase-resolved, sample-to-report HLA typing for 11 loci in a single assay, with a single workflow, on a single instrument, for dozens of samples simultaneously.

HLA-TAPAS (HLA-Typing At Protein for Association Studies) is an HLA-focused pipeline that can handle HLA reference panel construction (MakeReference), HLA imputation (SNP2HLA), and HLA association (HLAassoc). Briefly, major updates include (1) using PLINK-v1.9 instead of v1.07; (2) using BEAGLE v4.1 instead of v3 for phasing and imputation; and

TruSight HLA provides clinical researchers with a broad-coverage, ultra-high–resolution HLA typing solution for simple, rapid assessment of the HLA region. Using TruSight HLA, accurate, unambiguous, phase-resolved HLA typing can be achieved in a single assay. The sequencing panel’s expanded coverage provides the highest level of resolution.

2019年6月19日 · Here, we present HLA-VBSeq v2, a software application that makes use of a new Japanese HLA reference panel to enhance calling accuracy for Japanese HLA class-I genes. Our analysis showed...

This product is a panel of eleven (11) genetically modified cell lines targeting MHC Class I HLA molecules in a Jurkat T lymphocyte parental cell line background. The full HLA panel consists of a Beta-2 microglobulin (β2M) knockout cell line and an additional ten (10) monoallelic HLA expression cell lines.

One Lambda HybriType assay has been deigned to provide flexibility in testing configuration and coverage. This enables broad genetic coverage across diverse populations. Non-classical MHC Loci genotyping panel enables advanced compatibility research and extends testing beyond traditional HLA typing.